IFP Advisors Inc Buys 1,813 Shares of Eli Lilly and Company (NYSE:LLY)

IFP Advisors Inc boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 13.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,804 shares of the company's stock after buying an additional 1,813 shares during the period. IFP Advisors Inc's holdings in Eli Lilly and Company were worth $13,056,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Aspen Capital Management LLC bought a new position in shares of Eli Lilly and Company in the first quarter worth approximately $264,000. OneAscent Financial Services LLC raised its position in shares of Eli Lilly and Company by 117.3% in the 1st quarter. OneAscent Financial Services LLC now owns 10,428 shares of the company's stock worth $8,554,000 after purchasing an additional 5,630 shares during the last quarter. Morse Asset Management Inc raised its position in Eli Lilly and Company by 2.6% in the 1st quarter. Morse Asset Management Inc now owns 11,019 shares of the company's stock worth $9,101,000 after buying an additional 281 shares during the last quarter. National Mutual Insurance Federation of Agricultural Cooperatives grew its stake in shares of Eli Lilly and Company by 77.6% during the 1st quarter. National Mutual Insurance Federation of Agricultural Cooperatives now owns 34,800 shares of the company's stock valued at $28,742,000 after purchasing an additional 15,200 shares during the period. Finally, Elyxium Wealth LLC grew its stake in shares of Eli Lilly and Company by 220.8% during the 1st quarter. Elyxium Wealth LLC now owns 1,710 shares of the company's stock valued at $1,412,000 after acquiring an additional 1,177 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 2.5%

LLY traded up $19.46 during mid-day trading on Wednesday, hitting $795.90. The stock had a trading volume of 1,149,592 shares, compared to its average volume of 3,650,647. The stock's fifty day simple moving average is $767.03 and its 200-day simple moving average is $800.17. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The firm has a market capitalization of $754.31 billion, a price-to-earnings ratio of 64.74, a price-to-earnings-growth ratio of 1.10 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business's revenue was up 45.2% on a year-over-year basis. During the same period last year, the business earned $2.58 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is 48.82%.

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.